JWH-150
JWH-150 is a synthetic cannabinoid from the naphthoylindole family. It acts as a potent agonist for the cannabinoid receptors, specifically the CB1 and CB2 receptors. JWH-150 was developed by Dr. John W. Huffman and his team at Clemson University as part of their research into the structure-activity relationships of cannabinoids.
Chemical Structure and Properties[edit | edit source]
JWH-150 has the chemical formula C24H23NO and a molecular weight of 341.45 g/mol. It is structurally related to other compounds in the JWH series, such as JWH-018 and JWH-073. The compound features a naphthoyl group attached to an indole core, which is a common structural motif among synthetic cannabinoids.
Pharmacology[edit | edit source]
JWH-150 functions as a full agonist at both the CB1 and CB2 receptors. These receptors are part of the endocannabinoid system, which plays a role in regulating various physiological processes including pain sensation, mood, and appetite. The binding affinity of JWH-150 to these receptors is similar to that of other synthetic cannabinoids, making it a subject of interest in both medical research and recreational use.
Legal Status[edit | edit source]
The legal status of JWH-150 varies by country. In many jurisdictions, it is classified as a controlled substance due to its psychoactive effects and potential for abuse. For example, in the United States, JWH-150 is listed as a Schedule I controlled substance under the Controlled Substances Act.
Research and Applications[edit | edit source]
JWH-150 has been used in scientific research to study the endocannabinoid system and to develop new therapeutic agents. Its high affinity for cannabinoid receptors makes it a useful tool for understanding receptor function and for the development of new drugs targeting these pathways.
Safety and Toxicity[edit | edit source]
The safety profile of JWH-150 is not well-documented, but like other synthetic cannabinoids, it may pose significant health risks. Adverse effects can include tachycardia, hypertension, hallucinations, and psychosis. Long-term use may lead to dependence and withdrawal symptoms.
See Also[edit | edit source]
References[edit | edit source]
External Links[edit | edit source]
 | This medical article is a stub. You can help WikiMD by expanding it. |
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
